Truist Financial Corp grew its stake in Genmab A/S (NASDAQ:GMAB – Get Rating) by 37.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 20,578 shares of the company’s stock after acquiring an additional 5,568 shares during the period. Truist Financial Corp’s holdings in Genmab A/S were worth $662,000 as of its most recent filing with the SEC.
Several other large investors have also recently added to or reduced their stakes in the business. Wipfli Financial Advisors LLC purchased a new position in Genmab A/S during the 3rd quarter worth $171,000. Janney Montgomery Scott LLC raised its holdings in Genmab A/S by 8.0% in the third quarter. Janney Montgomery Scott LLC now owns 10,416 shares of the company’s stock valued at $335,000 after buying an additional 775 shares during the period. Legacy Wealth Asset Management LLC purchased a new stake in shares of Genmab A/S during the third quarter valued at approximately $514,000. Sawtooth Solutions LLC raised its stake in shares of Genmab A/S by 8.4% during the third quarter. Sawtooth Solutions LLC now owns 19,525 shares of the company’s stock valued at $627,000 after purchasing an additional 1,510 shares during the period. Finally, First Republic Investment Management Inc. increased its stake in shares of Genmab A/S by 22.9% in the second quarter. First Republic Investment Management Inc. now owns 73,746 shares of the company’s stock worth $2,396,000 after buying an additional 13,758 shares during the last quarter. 6.73% of the stock is owned by hedge funds and other institutional investors.
Genmab A/S Stock Performance
Shares of GMAB stock opened at $40.39 on Friday. Genmab A/S has a 52-week low of $26.19 and a 52-week high of $47.50. The company has a market capitalization of $26.64 billion, a price-to-earnings ratio of 33.11, a PEG ratio of 1.18 and a beta of 1.02. The company has a 50-day simple moving average of $43.35 and a two-hundred day simple moving average of $38.58.
Analysts Set New Price Targets
Several equities analysts have recently commented on GMAB shares. AlphaValue upgraded shares of Genmab A/S to a “reduce” rating in a research report on Thursday, November 17th. Deutsche Bank Aktiengesellschaft cut Genmab A/S from a “buy” rating to a “hold” rating in a research report on Friday, November 11th. Citigroup cut Genmab A/S from a “buy” rating to a “neutral” rating in a research report on Tuesday, December 20th. JPMorgan Chase & Co. increased their price objective on Genmab A/S from 3,450.00 to 3,600.00 and gave the stock an “overweight” rating in a research note on Tuesday, January 3rd. Finally, DNB Markets lowered Genmab A/S from a “buy” rating to a “hold” rating in a research report on Monday, October 17th. Two research analysts have rated the stock with a sell rating, ten have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $632.12.
About Genmab A/S
Genmab A/S operates as an international biotechnology company. The firm develops human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline include daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia.
- Get a free copy of the StockNews.com research report on Genmab A/S (GMAB)
- MarketBeat Week in Review – 1/16 – 1/20
- Does Old Dominion Show That Trucking Is Hitting The Brakes?
- Nordstrom Puts Fear Of Markdowns Into Retail Sector
- Exxon Mobil Stock: Within Striking Distance Of Buy Point
- High-Dividend-Yielding BHP Sees China Driving ’23 Growth
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.